HK2 and hepatocellular carcinoma: Inhibiting the key enzymes in this pathway, including HK2,13 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase‐3 (PFKFB3)14 and pyruvate kinase M2 (PKM2),15 could suppress the activation of hepatic stellate cells and the subsequent liver fibrosis, which is the main contributor to liver cirrhosis and HCC.